Merck Marks Beta Blocker Month: Revisiting a Landmark Discovery & Spotlight on Bisoprolol

Merck is commemorating Beta Blocker Month in June by celebrating the discovery of beta-blockers, their lasting impact on cardiovascular care, and the growing body of evidence supporting its innovator beta-blocker molecule, bisoprolol, in contemporary clinical practice.

More than six decades after the introduction of the first beta blocker, this therapeutic class continues to play a pivotal role in the management of hypertension, post-myocardial infarction (MI), chronic coronary syndromes, and heart failure, and patients. The occasion also highlights the growing body of evidence supporting bisoprolol, a highly β1-selective beta blocker, across diverse cardiovascular settings.

The Accidental Discovery of Beta Blockers

In 1958, Scottish pharmacologist Sir James Black had the idea of targeting a reduction in myocardial oxygen demand, instead of increasing its availability through vasodilation, during an angina attack. Inspired by Ahlquist's theory, Black's obsession was to find a drug capable of blocking the “excitatory” effect attributed to β-adrenergic receptors on the myocardium, thereby controlling heart rate¹.

Inspired by this idea, he explored the role of adrenaline and its interaction with cardiac receptors. His research led to the revolutionary concept of selectively blocking beta-adrenergic receptors to reduce the workload of the heart. This breakthrough resulted in the development of propranolol, the world's first clinically successful beta-blocker¹.

Initially developed to help patients with angina, beta blockers soon became an important component of treatment strategies for several cardiovascular conditions, including hypertension, arrhythmias, and heart failure. Sir James Black's contribution earned him the Nobel Prize in Physiology or Medicine in 1988 and helped revolutionize pharmacology from observing whole-organ responses to targeting specific molecular receptors, laying the foundation for modern receptor-based drug development.

The discovery of beta blockers is often considered serendipitous because scientists were initially attempting to treat angina pectoris by reducing the heart's oxygen demand, rather than developing a therapy that would ultimately transform cardiovascular medicine and influence multiple disease areas².

The Growing Burden of Cardiovascular Disease

India faces a disproportionately high burden of cardiovascular disease (CVD), characterized by earlier onset, elevated case fatality, and a greater proportion of premature deaths compared with global averages. Indian populations experience CVD nearly a decade earlier than Western counterparts, with approximately 62% of CVD-related deaths classified as premature.

The disability-adjusted life year (DALY) rate for ischemic heart disease is estimated to be 1.6 times the global average. A 2025 meta-analysis estimated the overall prevalence of CVD among Indian adults at approximately 11%, with a higher burden in urban populations (12%) compared with rural populations (6%)³.

Registry and real-world data from India indicate that β-blockers, including bisoprolol, remain among the most commonly prescribed antihypertensive agents³.

Bisoprolol: An International Innovation Story

Introduced in clinical practice in 1986, bisoprolol is a highly selective beta-1 adrenergic receptor blocker primarily used in the management of hypertension, angina, and heart failure. Developed during the evolution of cardio-selective beta blockers, it offered high β1-receptor selectivity and a pharmacological profile suited for long-term cardiovascular management.

Over the years, bisoprolol has been evaluated in landmark trials such as CIBIS, CIBIS II, and CIBIS III, which helped establish its role in heart failure management and contributed to its inclusion in international treatment guidelines⁴.

As of 2025, bisoprolol fumarate is included in the World Health Organization's Essential Medicines List and is estimated to be prescribed to nearly 23 million patients worldwide for long-term cardiovascular management. Its once-daily dosing schedule and availability across more than 127 countries have contributed to its widespread use in clinical practice⁵.

Recent Evidence Spotlight on Bisoprolol: Emerging as Preferred & Inclusive Beta-Blockers

Recent evidence continues to strengthen clinical confidence in bisoprolol across diverse patient populations.

• Data published in the Indian Heart Journal in 2025 reported that bisoprolol remains among the most frequently prescribed antihypertensive beta blockers in India³.
• The PACE 2026 study suggested that bisoprolol was well tolerated in patients with COPD and showed no adverse impact on cardiorespiratory health⁶.
• A 2025 Lancet meta-analysis reported a 25% reduction in mortality risk (HR 0.75; 95% CI 0.58–0.97) among post-MI patients with mildly reduced ejection fraction receiving beta-blocker therapy. Notably, 44% of patients included in the analysis were treated with bisoprolol⁷.
• In the ABYSS study, published in the European Heart Journal in 2025, Bisoprolol interruption was associated with an increase in heart rate of approximately 10 bpm, along with a rise of about 4 mmHg in both systolic and diastolic blood pressure.⁸.
• The JAPI May 2025 National Consensus Statement establishes bisoprolol as a preferred β₁-selective β-blocker for women across the cardiovascular (CV) continuum, addressing sex-specific differences in heart disease and hypertension⁹.
• Expert opinions from leading cardiologists across India further reinforce the role of bisoprolol as a first-line therapy in managing HFrEF and stable angina. Clinicians have also highlighted its suitability in patients with important comorbidities, including chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and diabetes¹⁰.

More than six decades since their discovery, beta blockers continue to play a vital role in cardiovascular medicine. From Sir James Black's early pioneering work to the substantial evidence supporting bisoprolol across the cardiovascular continuum, the journey of development of beta-blockers and the scientific milestones of bisoprolol highlight how a scientific breakthrough can evolve into a lasting therapeutic legacy that continues to benefit patients across the globe, helping them live longer and healthier with heart disease.

Abbreviations: MI: Myocardial Infarction, β1: Beta-1 Adrenergic Receptor, β-AR: Beta-Adrenergic Receptor, CVD: Cardiovascular Disease, DALY: Disability-Adjusted Life Year, CIBIS: Cardiac Insufficiency Bisoprolol Study, COPD: Chronic Obstructive Pulmonary Disease, HR: Hazard Ratio, CI: Confidence Interval, ABYSS: Assessment of Beta-blocker Interruption 1 Year after an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization, JAPI: Journal of the Association of Physicians of India, CV: Cardiovascular, HFrEF: Heart Failure with Reduced Ejection Fraction, CKD: Chronic Kidney Disease.